Onvatilimab Biosimilar - Research Grade

Human

VISTA

>1mg/ml

Human IgG1

https://www.imgt.org/mAb-DB/

ICH3002

Q9H7M9

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-VISTA antibody onvatilimab, expressed as a human IgG1 and supplied strictly for research use only (RUO). It is not the clinical drug and is not intended for human or veterinary use. The molecule is built around the VISTA (VSIR) target and is designed to reproduce the target-binding behaviour of the originator so investigators can use it as a well-characterised tool reagent rather than a formulated therapeutic. Typical applications include serving as a positive binding control, a benchmarking reference for assay development, and a defined input for in-vitro and preclinical mechanistic studies of the VISTA checkpoint axis. Material is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low endotoxin option (<0.5 EU/mg) suitable for endotoxin-sensitive functional and cell-based work, and can be supplied in bulk milligram-to-gram quantities to support screening campaigns, ADCC/ADC-development pipelines, and reproducible lot-to-lot experimentation. It is intended as a consistent, cost-effective analog for laboratory research. VISTA (V-type immunoglobulin domain-containing suppressor of T-cell activation; gene VSIR, also called C10orf54/PD-1H) is a type I transmembrane immune checkpoint protein of the B7 family, encoded by UniProt Q9H7M9. It is expressed most highly on myeloid cells (monocytes, macrophages, dendritic cells, neutrophils) and on regulatory and naive T cells. VISTA delivers inhibitory signals that suppress T-cell activation, proliferation and cytokine production, and it helps maintain peripheral tolerance and a quiescent naive T-cell state. It can act as both a ligand on antigen-presenting cells and a receptor on T cells, with ligand engagement (including pH-dependent binding to PSGL-1 in the acidic tumour microenvironment) contributing to immunosuppression. Because it restrains anti-tumour immunity and dampens inflammation, VISTA is studied as an immuno-oncology and autoimmunity target.

Platelet receptor Gi24, Stress-induced secreted protein-1, Sisp-1, V-set domain-containing immunoregulatory receptor, V-set immunoregulatory receptor, V-type immunoglobulin domain-containing suppressor of T-cell activation, VSIR, C10orf54

Detects human VISTA. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Onvatilimab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Onvatilimab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Onvatilimab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Onvatilimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Onvatilimab that binds human VISTA.